Key highlights
- Achieved greater than 95% SERPINA1 mRNA editing in repeat-dose animal models
- Increased total functional AAT protein concentrations by approximately 6-fold
- Reduced pathogenic hepatic Z-AAT protein levels by 95% in liver tissue
- Regulatory submission for clinical entry expected in the first half of 2027
- OPERA platform technology utilized for site-specific subcutaneous RNA correction
What Happened
Korro Bio released comprehensive preclinical data for its lead development program, KRRO-111, targeting Alpha-1 Antitrypsin Deficiency (AATD). The studies, conducted in mouse models and human hepatocytes, demonstrated that the RNA-editing candidate restored circulating functional M-AAT protein to 172 micromolar, representing a 6-fold increase over vehicle controls. Additionally, the therapy achieved a 95% reduction in whole-liver Z-AAT, the mutant protein responsible for hepatic injury. These results suggest a dual-action therapeutic profile capable of addressing both the pulmonary emphysema and hepatic cirrhosis typically associated with the PiZZ genotype of AATD.
Therapeutic Significance
“In these preclinical studies, KRRO-111 restored functional M-AAT while reducing the toxic Z-AAT that drives liver injury.”
Business Overview
Korro Bio is a clinical-stage biotechnology firm leveraging its proprietary OPERA platform to develop genetic medicines. The platform utilizes synthetic oligonucleotides to recruit endogenous ADAR enzymes, correcting genetic mutations at the RNA level without permanently altering DNA. Beyond KRRO-111, the company is advancing KRRO-121 for urea cycle disorders, with patient dosing in the Phase 2 ANCHOR clinical trial projected to begin in the first half of 2027. This RNA-based approach aims to provide the benefits of genetic correction with a redosable subcutaneous drug presentation.
Financial and Market Context
- Company held cash and marketable securities of $137.9 million as of August 2026
- Liquidity is projected to fund operational requirements into the second half of 2028
- Reported annual revenue currently stands at $6.39 million from research collaborations
- As a clinical-stage biotech, the firm currently maintains a zero-product order backlog
- Stock technicals show a 19.22% decline over the last quarter with an RSI of 42.7
Up 36.8% since our story on 22 Oct: $9.29 when we broke it → $12.71 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $8.91 |
|---|---|
| 20 Oct | $9.44 |
| 21 Oct | $9.29 |
| 22 Oct | $12.05 |
| 23 Oct | $11.98 |
| 26 Oct | $12.02 |
| 27 Oct | $13.30 |
| 28 Oct | $13.86 |
| 29 Oct | $14.20 |
| 30 Oct | $14.31 |
| 2 Nov | $15.85 |
| 3 Nov | $15.86 |
| 4 Nov | $16.62 |
| 5 Nov | $14.73 |
| 6 Nov | $14.75 |
| 9 Nov | $14.96 |
| 10 Nov | $15.73 |
| 11 Nov | $14.41 |
| 12 Nov | $14.31 |
| 13 Nov | $13.61 |
| 16 Nov | $12.71 |
Management commentary
“In these preclinical studies, KRRO-111 restored functional M-AAT while reducing the toxic Z-AAT that drives liver injury.”
“Based on the strength and consistency of these data, we believe KRRO-111 has the potential to become a transformative therapy for both the lung and liver manifestations of AATD, and we look forward to advancing it into the clinic in the first half of 2027.”
| Share price | $9.29 |
|---|---|
| Market cap | $137M |
| Revenue (annual) | $6M |
| 1-month price change | -6.91% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Korro Bio, Inc. announcing preclinical results for KRRO-111 in Alpha-1 Antitrypsin Deficiency.
Track Korro Bio, Inc. live
Get the next Korro Bio, Inc. SEC filing seconds after it lands.